Pivoting Research to Fight COVID-19: Stabilizing and Delivering Antivirals, Antibodies and Vaccines Using Thin Film Freezing
Sahakijpijarn S, Moon C, Xu H, Cui Z, Williams III RO.
Respiratory Drug Delivery 2022. Volume , 2022: 21-28.
Abstract:
During the Coronavirus 2019 (COVID-19) pandemic, the quest for more effective and accessible treatments and preventatives is critical. Thin-film freezing (TFF) is a bottom-up particle engineering technology with the potential to prepare stable dry powders of various active compounds. Due to the unique properties of TFF-derived powder, it has been applied for pulmonary drug delivery. This paper describes the benefits and applications of TFF as highlighted by our pivot to COVID-19 related research to develop antivirals, monoclonal antibody, small interference RNA (siRNA), and vaccines as dry powders suitable for, among other applications, pulmonary drug delivery. The pandemic provided the motivation to apply TFF to COVID-19 related low molecular weight anti-viral drugs and biologics, and to expand its application to a plethora of other biologics and vaccines beset by formulation design and cold-chain storage stability challenges.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
